Company Overview of Attenuon, LLC
Attenuon, LLC, a clinical-stage biopharmaceutical company, develops cancer therapeutics to disrupt cellular signaling processes to tumor growth and metastatsis. It offers ATN-224 that disrupts signaling pathways involved in tumor growth, angiogenesis, and metastasis, including those mediated by multiple kinases, as well as NF-kappaB by inhibiting the enzyme superoxide dismutase; and ATN-161, a five-amino acid peptide derived from fibronectin. The company was founded in 1998 and is based in San Diego, California.
11535 Sorrento Valley Road
San Diego, CA 92121
Founded in 1998
Key Executives for Attenuon, LLC
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Attenuon, LLC, please visit www.attenuon.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.